TIL for Patients With Advanced Solid Tumor
Summary
Background: Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to patients. TIL therapy has shown strong efficacy for the treatment of solid tumors and has achieved high objective response rates in multiple cancers, such as melanoma, NSCLC, and cervical cancer. Objective: To evaluate the safety and efficacy of TIL for the patients with advanced solid tumor. Eligibility: Adults aging 18-75 with advanced solid tumor. Design: 1. Patients will undergo screening tests, including imaging procedures, heart and lung tests, and lab tests. 2. Freshly resected patient tumors were dissected by the surgeon. 3. TIL cells were isolated from the patient's tumor tissue, then cultured in vitro, activated and expanded. 4. At last TIL cells will be re-infused into the patients.
Timeline
- Start
- 2023-05-30
- Primary completion
- 2025-01-31
- Completion
- 2025-07-31
Outcome
Outcome not reported
Stopped (Business): “Portfolio prioritization”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous tumor-infiltrating lymphocyte cells | Cell therapy | — | — |